Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2018 3
2021 1
2022 3
2023 4
2024 7
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial.
van der Wilk BJ, Eyck BM, Wijnhoven BPL, Lagarde SM, Rosman C, Noordman BJ, Valkema MJ, Bisseling TM, Coene PLO, van Det MJ, Dekker JWT, van Dieren JM, Doukas M, van Esser S, Fiets WE, Hartgrink HH, Heisterkamp J, Holster IL, Klarenbeek B, van Klaveren D, Kouw E, Kouwenhoven EA, Luyer MD, Mostert B, Nieuwenhuijzen GAP, Oostenbrug LE, Pierie JP, van Sandick JW, Sosef MN, Spaander MCW, Valkema R, van der Zaag ES, Steyerberg EW, van Lanschot JJB; SANO Study Group. van der Wilk BJ, et al. Lancet Oncol. 2025 Apr;26(4):425-436. doi: 10.1016/S1470-2045(25)00027-0. Epub 2025 Mar 17. Lancet Oncol. 2025. PMID: 40112851 Clinical Trial.
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Cats A, et al. Lancet Oncol. 2018 May;19(5):616-628. doi: 10.1016/S1470-2045(18)30132-3. Epub 2018 Apr 9. Lancet Oncol. 2018. PMID: 29650363 Clinical Trial.
Risk of lymph node metastasis in pT2 rectal cancer: a nationwide retrospective analysis.
Albers SC, Geitenbeek RTJ, van Geffen EGM, Sluckin TC, Hazen SJA, Kusters M, Tanis PJ, Consten ECJ, Dekker E, Bastiaansen BAJ, Wiggers JK, Hompes R; Dutch Snapshot Research Group and MIRECA (Taskforce for Minimally Invasive Rectal Carcinoma surgery). Albers SC, et al. Br J Surg. 2025 Feb 1;112(2):znaf028. doi: 10.1093/bjs/znaf028. Br J Surg. 2025. PMID: 39982377 No abstract available.
Salvageable locoregional recurrence and stoma rate after local excision of pT1-2 rectal cancer - A nationwide cross-sectional cohort study.
Moolenaar LR, van Geffen EGM, Hazen SJA, Sluckin TC, Beets GL, Leijtens JWA, Talsma AK, de Wilt JHW, Tanis PJ, Kusters M, Hompes R, Tuynman JB; Dutch Snapshot Research Group; Collaborators Snapshot Registry. Moolenaar LR, et al. Eur J Surg Oncol. 2025 Jun;51(6):109623. doi: 10.1016/j.ejso.2025.109623. Epub 2025 Jan 23. Eur J Surg Oncol. 2025. PMID: 40009914 Free article.
Optimised treatment of patients with enlarged lateral lymph nodes in rectal cancer: protocol of an international, multicentre, prospective registration study after extensive multidisciplinary training (LaNoReC).
van Geffen EGM, Sluckin TC, Hazen SJA, Horsthuis K, Intven M, van Dieren S, Beets G, Lange MM, Taggart MW, Beets-Tan RGH, Marijnen CAM, Konishi T, Tanis PJ, Kusters M; LaNoReC study group. van Geffen EGM, et al. BMJ Open. 2024 Oct 16;14(10):e083225. doi: 10.1136/bmjopen-2023-083225. BMJ Open. 2024. PMID: 39414276 Free PMC article.
Coverage of Lateral Lymph Nodes in Rectal Cancer Patients with Routine Radiation Therapy Practice and Associated Locoregional Recurrence Rates.
Sluckin TC, Hazen SJA, Horsthuis K, Beets-Tan RGH, Antonisse IE, Berbée M, van Bockel LW, Boer AH, Ceha HM, Cnossen JS, Geijsen ED, den Hartogh MD, Hendriksen EM, Intven MPW, Leseman-Hoogenboom MM, Meijnen P, Muller K, Oppedijk V, Rozema T, Rütten H, Spruit PH, Stam TC, Velema LA, Verrijssen AE, Vos-Westerman J, Tanis PJ, Marijnen CAM, Kusters M; Dutch Snapshot Research Group. Sluckin TC, et al. Among authors: hendriksen em. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):422-433. doi: 10.1016/j.ijrobp.2023.04.013. Epub 2023 Apr 28. Int J Radiat Oncol Biol Phys. 2023. PMID: 37120027
The association between hospital variation in curative treatment for esophagogastric cancer and health-related quality of life and survival.
Vissers PAJ, Luijten JCHBM, Lemmens VEPP, van Laarhoven HWM, Slingerland M, Wijnhoven BPL, Rosman C, Mook S, Heisterkamp J, Hendriksen EM, Gisbertz SS, Nieuwenhuijzen GAP, Verhoeven RHA. Vissers PAJ, et al. Among authors: hendriksen em. Eur J Surg Oncol. 2023 Oct;49(10):107019. doi: 10.1016/j.ejso.2023.107019. Epub 2023 Aug 12. Eur J Surg Oncol. 2023. PMID: 37659340 Free article.
23 results